WO2003104259A2 - Peptides presentes par des molecules hla-b18 et hla-cw16 et utilisations de ces peptides - Google Patents

Peptides presentes par des molecules hla-b18 et hla-cw16 et utilisations de ces peptides Download PDF

Info

Publication number
WO2003104259A2
WO2003104259A2 PCT/US2003/017641 US0317641W WO03104259A2 WO 2003104259 A2 WO2003104259 A2 WO 2003104259A2 US 0317641 W US0317641 W US 0317641W WO 03104259 A2 WO03104259 A2 WO 03104259A2
Authority
WO
WIPO (PCT)
Prior art keywords
cells
peptide
hla
mage
complexes
Prior art date
Application number
PCT/US2003/017641
Other languages
English (en)
Other versions
WO2003104259A3 (fr
Inventor
Janine Bilsborough
Yi Zhang
Erwin Schultz
Christophe Panichelli
Pierre Van Der Bruggen
Thierry Boon-Falleur
Catia Traversari
Original Assignee
Ludwig Institute For Cancer Research
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from US10/164,121 external-priority patent/US20030228308A1/en
Priority claimed from US10/164,078 external-priority patent/US7041502B2/en
Application filed by Ludwig Institute For Cancer Research filed Critical Ludwig Institute For Cancer Research
Priority to AU2003249693A priority Critical patent/AU2003249693A1/en
Publication of WO2003104259A2 publication Critical patent/WO2003104259A2/fr
Publication of WO2003104259A3 publication Critical patent/WO2003104259A3/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4748—Tumour specific antigens; Tumour rejection antigen precursors [TRAP], e.g. MAGE
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0011—Cancer antigens
    • A61K39/001184—Cancer testis antigens, e.g. SSX, BAGE, GAGE or SAGE
    • A61K39/001186—MAGE
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/46—Cellular immunotherapy
    • A61K39/461—Cellular immunotherapy characterised by the cell type used
    • A61K39/4611—T-cells, e.g. tumor infiltrating lymphocytes [TIL], lymphokine-activated killer cells [LAK] or regulatory T cells [Treg]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/46—Cellular immunotherapy
    • A61K39/464—Cellular immunotherapy characterised by the antigen targeted or presented
    • A61K39/4643—Vertebrate antigens
    • A61K39/4644—Cancer antigens
    • A61K39/464484—Cancer testis antigens, e.g. SSX, BAGE, GAGE or SAGE
    • A61K39/464486—MAGE
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • C12Q1/6886—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/57484—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumor, cancer, neoplasia, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides, metabolites
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/515—Animal cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies

Definitions

  • This invention relates to peptides which form immunologically active complexes with MHC molecules. More particularly, it involves peptides based upon amino acid sequences found in the sequences of MAGE molecules, such as MAGE- 1 and MAGES " molecule referred to as "MAGE-3,”] which form complexes with [the] MHC molecules, such as HLA-Cw6 and Bl 8. [ HLA-B 18.]
  • tum " antigen presenting cell lines are immunogenic variants obtained by mutagenesis of mouse tumor cells or cell lines, as described by Boon, et al., J. Exp. Med. 152:1184-1193 (1980), the disclosure of which is incorporated by reference.
  • tum " antigens are obtained by mutating tumor cells which do not generate an immune response in syngeneic mice and will form tumors (i.e., "tum + " cells). When these tum + cells are mutagenized, they are rejected by syngeneic mice, and fail to form tumors (thus "turn " ").
  • Boon, et al., Proc. Natl. Acad. Sci USA 74:272 (1977) the disclosure of which is incorporated by reference. Many tumor types have been shown to exhibit this phenomenon. See, e.g., Frost, et al., Cancer Res. 43:125 (1983).
  • tum " variants fail to form progressive tumors because they elicit an immune rejection process.
  • the evidence in favor of this hypothesis includes the ability of "turn " " variants of tumors, i.e., those which do not normally form tumors, to do so in mice with immune systems suppressed by sublethal irradiation, Van Pel, et al. Proc. Natl, Acad. Sci. USA 76:5282-5285 (1979); and the observation that intraperitoneally injected tum " cells of mastocytoma P815 multiply exponentially for 12-15 days, and then are eliminated in only a few days in the midst of an influx of lymphocytes and macrophages (Uyttenhove. et al., J. Exp.
  • mice acquire an immune memory which permits them to resist subsequent challenge to the same tum " variant, even when im unosuppressive amounts of radiation are administered, with the following challenge of cells (Boon, et al., Proc. Natl, Acad. Sci. USA 74:272-275 (1977); Van Pel, et al., supra: Uyttenhove. et al, supra). Later research found that when spontaneous tumors were subjected to mutagenesis, immunogenic variants were produced which did generate a response. Indeed, these variants were able to elicit an immune protective response against the original tumor. See Van Pel, et al., J. Exp. Med.
  • TRAs may or may not elicit antibody responses.
  • CTL cytolytic T cell
  • a tumor exemplary of the subject matter described supra is known as P815. See DePlaen. et al, Proc. Natl. Acad. Sci. USA 85:2274-2278 (1988); Sikora. et al., EMBO J 9:1041-1050 (1990), and Sibille. et al., J. Exp. Med. 172:35-45 (1990), the disclosures of which are incorporated by reference.
  • the P815 tumor is a mastocytoma, induced in a DBA/2 mouse with methylcholanthrene and cultured as both an in vitro tumor and a cell line.
  • the P815 line has generated many tum " variants following mutagenesis, including variants referred to as P91A (DePlaen.
  • tum antigens are only present after the tumor cells are mutagenized. Tumor rejection antigens are present on cells of a given tumor without mutagenesis.
  • a cell line can be tum + , such as the line referred to as "PI”, and can be provoked to produce tum " variants.
  • MAGE-1 U.S. Patent No. 5,342,774, the disclosure of which is incorporated by reference, disclosed three members of a family of the genes referred to hereafter as the "MAGE" family of genes. MAGE-1, 2 and 3 are disclosed therein. Also see Traversari. et al., J. Exp. Med 176:1453-1457 (1993); Science 254:1643-147 (1991), the disclosures of which are incorporated by reference. Additional members of the MAGE family have been discovered and are disclosed in, e.g., DePlaen. et al., hnmunogenetics 40:360 (1994), and U.S. Patent No. 5,612,201 to DePlaen. both of which are incorporated by reference. With respect to MAGE-1, in addition to the '774 patent, see e.g. U.S. Patent No. 5,925,729.
  • the genes are useful as a source for the isolated and purified tumor rejection antigen precursor and the TRA themselves, either of which can be used as an agent for treating the cancer for which the antigen is a "marker", as well as in various diagnostic and surveillance approaches to oncology, discussed infra.
  • tum " cells can be used to generate CTLs which lyse cells presenting different tum " cells can be used to generate CTLs which lyse cells presenting different tum " antigens as well as tum cells. See, e.g., Maryanski. et al., Eur. J. Immunol 12:401 (1982); and Van den Eynde.
  • the tumor rejection antigen precursor may be expressed in cells transfected by the gene, and then used to generate an immune response against a tumor of interest.
  • MLTC autologous mixed lymphocyte-tumor cell cultures
  • HLAs human leukocyte antigens
  • Additional peptides have been identified which consist of amino acid sequences found in molecules such as MAGE-1 and MAGE-3 /MAGE-3], but which bind to different MHC molecules. See, e.g., U.S. Patent Nos. 5,554,506, 5,585,461, 5,591,430 and 6,091,987 which describe MAGE-3 peptides which bind to HLA-A2 molecules, and also see U.S. Patent Nos. 5,965,535, 6,291,430 and 6,369,211, which teach MAGE-3 peptides consisting of amino acid sequences found in MAGE-3, which bind to MHC Class II molecules. See, e.g., Tanzarella. et al., Cane. Res.
  • Additional peptides have been identified which consist of amino acid sequences found in MAGE-1, but which bind to different MHC molecules. Also see, e.g., U.S. Patent Nos. 5,405,940 and 5,925,729 which describe peptides which bind to HLA-A1 molecules, and also see U.S. Patent Nos. 5,558,995 and 6,228,971, which teach peptides consisting of amino acid sequences found in MAGE-1, which bind to HLA-Cw*1601 molecules. CTLs obtained from two melanoma patients after mixed lymphocyte-tumor cell cultures have been found to recognized MAGE-1 based peptides presented by HLA- Al, B37 and Cwl6 molecules.
  • HLA-A3 Choaux. et al., J. Immunol 163:2928-2836 (1999); A68 (Chaux, et al, ibid.) B7 (Luiten. et al., Tissue Antigens 55:149:152 (2000)), B35 (Luiten, et al., Tissue Antigens 56:77-81 (2000)); B53 (Chaux, et al, supra): Cw2 (Chaux. et al, supra): Cw3 (Chaux, et al, supra.: DR13 (Chaux, et al., J. Exp. Med. 189:767-78 (1999); and DR15 (Chaux. et al., Eur. J. hnmunol 31:1910-6 (2001)). These are also incorporated by reference in their entirety.
  • MAGE-1 is expressed in a variety of cancers. Data indicate that it is expressed in 53% of esphoageal cancers, 49% of non-small cell lung carcinoma, and 48% of metastatic melanomas. See, e.g., Boon, et al., "Cancer Vaccines: Cancer Antigens, Shared Tumor Specific Antigens” in Rosenberg, ed., Principles and Practice of The Biologic Therapy of Cancer (Philadelphia, JB Lippincott Williams & Wilkins, 2000), pp. 493-504; Van den Eynde.
  • MAGE-3 is expressed is about 75% of metastatic melanomas, and in 35-50% of esophageal, head and neck, lung, and bladder carcinomas. See, e.g., Gaugler. et al., supra. Boon, et al., Cancer Vaccines: Cancer Antigens, Shared Tumor Specific Antigens" in Rosenberg, ed., Principles and Practice of The Biologic Therapy of Cancer (Philadelphia, ' JB Lippincott Williams & Wilkins, 2000), pp. 493-504. Hence, there is interest in having additional methodologies available for identifying peptides consisting of sequences found in MAGE-3, especially those which form complexes with MHC molecules other than those set forth, supra.
  • MAGE-3 peptide previously identified as a T cell epitope for HLA-B44, is also an epitope for HLA-B18.
  • MAGE-1 peptide known to bind HLA-Cw3 & Cwl6 is a T cell epitope for HLA-Cw6.
  • This example describes the construction of an adenovirus based vector which expresses MAGE-3, and the infection of monocyte derived, dendritic cells thereby.
  • Ad.MAGE-3 The recombinant adenovirus, referred to as "Adeno.MAGE-3,” was generated via in vivo homologous recombination in 293-EBNA cells, described by Graham, et al., J. Gen. Virol. 36:59-72 (1977), that had been transformed with an adenovirus of type V (ATCC:CRL 1573). These 293-EBNA cells were typed as HLA- A3, B7, Cw7 and were positive for expression of MHC Class I expression, when tested with Class I specific monoclonal antibody W6/32, as described by Parham. et al., J. Immunol. 123:342-9 (1979).
  • Adeno.MAGE-3 was generated via overlapping adenoviral sequences in pAd- CMVIcpA-MAGE-3, and restriction cleaved viral DNA of defective strain dI324, in accordance with Stratford-Perri caudet et al., J. Clin. Invest. 90:626-630 (1992), incorporated by reference.
  • the 293 cells were cotransfected with 5 ⁇ g each of linearized plasmid pAd-CMVIcpA-MAGE-3 and the large, Clal DNA fragment of dI324.
  • Recombinant adenovirus was plaque purified, and the presence of the transgene was assessed via restriction analysis.
  • Recombinant adenovirus was propagated in 293 cells, purified by double cesium chloride density centrifugation, and dialyzed extensively. Viral stocks were stored in aliquots with 10% glycerol, at -80°C, and were titred by plaque assay, using 293 cells, as necessary.
  • the dendritic cells were obtained by starting with peripheral blood from a hemochromatosis patient, as a standard buffy coat preparation. The preparations were laid down on a 15 ml Lymphoprep layer, in 50 ml tubes. Contamination by platelets was minimized by centrifuging the tubes at 1,000 rpm for 20 minutes at room temperature. The top 20-25mls were removed, as these contain most of the platelets and tubes were then centrifuged at 1500 rpm for 20 minutes, at room temperature. The interphase containing PBMCs were harvested, and washed at least 3 times in cold, phosphate buffer solution containing 2mM EDTA, so as to eliminate the remaining platelets.
  • dendritic cells were infected with Adeno.MAGE-3, by combining 3x10 6 cells with the adenovirus, at a multiplicity of infection ("MOI" hereinafter) of 30, in 200 ⁇ l of complete RPMI medium at 37°C, under 5% CO 2 . Infected dendritic cells were washed after 2 hours.
  • MOI multiplicity of infection
  • This example describes how the adenovirus infected dendritic cells were used to stimulate autologous CD8 + T lymphocytes.
  • CD8 + cells had been isolated, and frozen. The day before stimulation experiments, the CD8 + cells were thawed and grown overnight in IMDM, supplemented with 10% human serum, AAG and antibiotics, (complete IMDM), together with lOU/ml ofIL-2.
  • Autologous responder CD8 + T lymphocytes were then mixed (1.5xl0 5 cells), with infected dendritic cells (3x10 4 ), in U bottomed microwells in 200 ⁇ l of complete IMDM, together with IL-6 (lOOOU/ml), and IL-12 (lOng/ml).
  • autologous dendritic cells were thawed, infected with the Adeno. -MAGE-3 vector as described supra, an used for stimulating the responder cells, in medium supplemented with IL-2 (lOU/ml), and IL-7 (5ng/ml).
  • CD8 + cells stimulated in example 2 were used in this example. As indicated, they were tested for lytic activity on day 28.
  • the target of the CD8 + cells was autologous, EBV-B cells that had been infected with either vaccinia-MAGE-3, or control vaccinia virus.
  • EBV-B transformed B cell line was derived from the blood cells of the hemochromatosis blood donor referred to supra, by culturing isolated B cells with 20% of a supernatant of EBV-transformed, B95-8 cells, available from the American Type Culture Collection (CRL 1612), in the presence of l ⁇ g/ml of cyclosporin A.
  • the cells were cultured in Iscove's modified Dulbecco medium, supplemented with 10% fetal calf serum, 0.24mM L-asparagine, 0.55mM L-arginine, and 1.5mM L-glutamine, as well as lOOU/ml penicillin and lOO ⁇ g/ml streptomycin.
  • vaccinia-MAGE-3 In order to transfect the EBV-B cells, a readily available vaccinia-MAGE-3 was used. Virus particles were sonicated for 1 minute before use. Following sonication, 2x10 6 EBV-B cells were combined with the particles for 2 hours, at an MOI of 20, in 150 ⁇ l of complete RPMI medium. The infected cells were washed, labelled with lOO ⁇ Ci of Na( 51 Cr)O 4 , and were then added to the CD8 + cells described supra, at an effector:target ratio of 40:1.
  • T cells were stimulated with 4x10 3 irradiated (lOOGy) EBV-B cells that had been infected with Yersinia.MAGE-3 ⁇ -196 , and 4x10 3 EBV-B cells that had been infected with Yersinia.MAGE-3 14 -314 .
  • Yersinia constructs were used to avoid T cell responses to adenovirus proteins.
  • Allogenic EBV-B cells (lxl 0 4 LG2-EBV-B cells per well) were used as feeder cells.
  • Yersinia transfected EBV-B cells were prepared, using strain MRS40(pABL403), as described by Boland, et al., Infect, humun. 66:1878-84 (1988), incorporated by reference.
  • the strain encodes mutated or truncated toxic Yop proteins, but maintains its ability to translocate proteins in fusion with truncated YopE into the cytosol of eukaryotic cells, but does not elicit cytotoxicity, and is used as a vector to inject protein into the cytosol of eukaryotic cells.
  • a first construct containing amino acids 1-196 of MAGE-3 was inserted, in frame, with a sequence encoding the first 130 amino acids of YopE, into vector pMS621, described by Gary, et al., Mol. Microbiol. 14:583-94 (1994), incorporated by reference. Similarly, a construct was made which encoded amino acids 147-314 of MAGE-3. Either of these plasmids were electroporated into E.coli strain SM10, and then mobilized into Yersinia enterocolitica MRS40.
  • the recombinant MRS40 clones were selected on agar containing medium, supplemented with 35 ⁇ g/ml nalidixic acid, ImM sodium m-arsenite, and 12 ⁇ g/ml of chloramphenicol, in accordance with Neyt, et al., J. Bacteriol 179:612-9 (1997).
  • Colonies containing Yersinia constructs encoding the MAGE-3 constructs described supra were grown overnight at 28°C in LB medium, and was then diluted to obtain an OD of 0.2 at 600nm, and was then cultured at 28°C for about 2 hours.
  • Bacteria were washed in 0.9% NaCl, and resuspended, at 10 8 bacteria per ml, in 0.9% NaCl, assuming that a culture giving and OD 60 o equals one containing 5x10 s bacteria per ml.
  • EBV-B cells that had been irradiated at lOOGys were resuspended at 10 6 cells in 3.8 ml of RPMI, without antibiotics, supplemented with 10%FCS and AAG. Then, 200 ⁇ l of the bacterial suspension were added, and after two hours of infection, the cells were incubated for an additional 2 hours with 30 ⁇ g/ml gentamycin, and then were washed, three times, prior to use as stimulator cells, as described supra.
  • CTL22 A CTL clone was obtained, which will be referred to thereafter as CTL22.
  • the MAGE-3 -encoding retro viral vector plasmids MFG-MAGE-3 was introduced into PhoenixAMPHO packaging cells by transfection.
  • the transfection procedure is a modification of the calcium phosphate-mediated transfection protocol of Graham and van der Eb, Virology 52(2):456:67 (1973), incorporated by reference.
  • PhoenixAMPHO cells were plated in cell growth medium in a 75 cm 2 tissue culture flask. After adding the cells, the flask was gently shaken forward and backward to distribute cells evenly about the flask bottom. The cells were incubated at 37°C in a 5% Co atmosphere.
  • transfection cocktail was prepared in a 50 ml tube by adding 40 ⁇ g retroviral vector plasmid DNA to water and diluting to 1575 ⁇ l final volume. To this DNA solution, 225 ⁇ l of 2 M CaCl 2 was added.
  • the PhoenixAMPHO medium was removed and gently replaced by 9 ml of ID medium containing only 2.5%) FCS.
  • the retroviral supernatant was harvested 48 hours after transfection by removing the medium from the cells and filtering through a 0.45 ⁇ m filter to remove cell debris. After harvest and filtration, the virus-containing medium was kept on ice, aliquoted in appropriate volumes in 15 ml polypropylene tubes and stored at -80°C.
  • Target cells were resuspended in 60mm tissue culture plates at a density of 10 cells in 4 ml of infection cocktail containing 50% viral supernatant in growth medium and 6 ⁇ g/ml of protamine sulfate. The plates were centrfuged for 2 hours at 32°C and 1200 rpm, followed by another 2 hours of incubation in a humidified incubator at 37°C. Cells were then transferred to 4 ml of growth medium. This transduction cycle was carried out immediately after plating the cells and was repeated at 24 and 48 hours.
  • the cell donor had been HLA typed previously as HLA-A2, A3, B*1801, B* 1501101, Cw*0304, and Cw*0501 positive.
  • HLA-A2 A3, B*1801, B* 1501101, Cw*0304, and Cw*0501 positive.
  • autologous EBV-B cell lines which expressed A2 or A3 were pulsed with the active peptide, and were not lysed by CTL22. This, of course, suggested that one of the HLA-B or C molecules was responsible for peptide presentation.
  • the 293-EBNA cells were distributed (5x104 cells), in flat bottomed microwells, and were transfected, one day later, with MAGE-3 cDNA inserted into pcDNAI/Amp, and cDNA encoding one of the HLA-B and C molecules supra, also inserted in pcDNA3.
  • the transfection utilized 5x10 4 293-EBNA cells, and 50ng of each of the cDNA molecules, together with l ⁇ l of lipofectamine.
  • 3000 CTL22 cells were added, in a total volume of 150 ⁇ l of complete IMDM, supplemented with 25U/ml of IL-2.
  • TNF secretion assay was carried out, in accordance with Traversari, et al., Immunogenetics 35:145-152 (1992) incorporated reference, except that 20mM of LiCl were added during incubation with supernatant of TNF sensitive, WEHI-164cl3 cells. See Beyaert. et al., Proc. Natl. Acad. Sci. USA 86:9494-8 (1989); Espevik. et al., J.Immunol Meth. 95:99-105 (1986).
  • cell line LCL 721.221 was tested, because it is an EBV derived cell line that does not express HLA Class-I molecules on its surface. Five million cells were electroporated with 50ng of pcDNA3 containing the coding sequence of either B*1801 or B* 1501101, using a single pulse at 260 volts, 1575ohms, and 1,050 farads.
  • Cells were selected based upon resistance to 1.5mg ml geniticin, and were also tested and isolated for HLA expression via flow cytometry and labeling with anti-HLA- A, -B, or -C antibody B 1.23.2, in accordance with Rebai. et al., Tissue Antigens 22:107- 117 (1983), incorporated by reference.
  • transfectants were then incubated with the active peptide in a 51 Cr lysis assay as described supra. Only HLA-B* 1801 cells were lysed.
  • AVAC-1 monocyte derived dendritic cells were infected with a canarypox virus that had been engineered to contain the MAGE-1 coding sequence.
  • the construct referred to as "ALVAC-1" hereafter, was obtained from a commercial source.
  • Peripheral blood cells were obtained from a hemochromatosis patient as standard, buffy coat preparations. These preps were laid down on a 15ml Lymphoprep layer, in 50ml tubes. Contamination of the PBMCs by platelets was minimized by centrifuging the samples for 20 minutes at room temperature at lOOOrpms, followed by removal of the top 20-25mls, which contain most of the platelets. The tubes were then recentrifuged, at 1500 rpms for twenty minutes, at room temperature. The interphases, which contain the PBMCs, were harvested and washed at least 3 times in cold phosphate buffer solution containing 2mM EDTA, to eliminate the remaining platelets.
  • Antologous dendritic cells were then generated by depleting PBMCs from T lymphocytes, via resetting with sheep erythrocytes that had been treated with 2- aminoethyliso thiouronium. Rosetted T cells were then treated with NH 4 C1 (160mM), in order to lyse the sheep erythrocytes, and were then washed.
  • the CD8 + T lymphocytes in the preps were isolated from the rosetted T cells by positive selection, using an anti CD8 + monoclonal antibody, coupled to magnetic microbeads. The resulting dendritic cells were sorted through a magnet, and frozen until needed.
  • This example describes how the infected dendritic cells were used to stimulate autologous CD8 + T lymphocytes.
  • CD8 + cells had been isolated, and frozen. The day before stimulation experiments, the CD8 + cells were thawed and grown overnight in IMDM, supplemented with 10% human serum, AAG and antibiotics, (complete IMDM), together with 5U/ml of IL-2. These autologous responder CD8 + T lymphocytes were then mixed (1.5xl0 5 cells), with infected, dendritic cells (3x10 4 ), in U bottomed microwells in 200 ⁇ l of complete IMDM, in the presence of IL-6 (lOOOU/ml), and IL-12 (lOng/ml).
  • CD8 + cells stimulated in example 2 were used in this example. As indicated, they were tested for lytic activity on day 21 of the stimulation experiment described in example 2.
  • the targets of the CD8 + cells were autologous, EBV-B cells that had been infected with either a vaccinia-MAGE-1 virus construct, or control vaccinia virus.
  • EBV-B transformed B cell line was derived from the blood cells of the hemochromatosis blood donor referred to supra, by culturing isolated B cells with 20% of a supernatant of EBV-transformed, B95-8 cells, available from the American Type Culture Collection (CRL 1612), in the presence of 1 ⁇ g/ml of cyclosporin A.
  • the cells were cultured in Iscove's modified Dulbecco medium, supplemented with 10% fetal calf serum, 0.24mM L-asparagine, 0.55mM L-arginine, and 1.5mM L-glutamine, as well as lOOU/ml penicillin and lOO ⁇ g/ml streptomycin.
  • vaccinia construct In order to transfect the EBV-B cells, a readily available vaccinia construct was used, together with parental vaccinia virus as control.
  • the vaccinia construct is referred to, alternatively, as "WR-MAGE-A1" or "vaccinia-MAGE-1.” It encodes the entire MAGE-1 protein.
  • Virus particles were sonicated for 30 seconds before use. Following sonication, infection was performed on 2x10 6 target EBV-B cells for 2 hours, using an MOI of 20, in 200 ⁇ l of complete RPMI medium. Infected cells were washed, labelled with lOO ⁇ Ci of Na( 51 Cr)O , and added to the CD8 + cells described supra, at an effector:target ratio of 40:1.
  • T cells which exhibited activity were taken out of the microcultures described supra.
  • the T cells were cloned in U bottomed microplates via limiting dilution, in complete IMDM medium supplemented with IL-2 (50U/ml), IL-4 (5U/ml), and IL-7 (5ng/ml).
  • T cells were stimulated weekly, via addition of phytohemagglutinin, or EBV- B cells that had been transduced with a retroviral construct which encoded MAGE-1, "retro-MAGE-l.NGFR". These transduced cells were irradiated (lOOGy).
  • the retro-MAGE-l.NGFR construct was used in order to stimulate anti-MAGE-1 CTLs, and to avoid proliferation of CTLs against adenoviral vector components.
  • the retro-MAGE-l.NGFR construct is derived from LXSN backbone, which is derived from Maloney murine leukemia virus. It encodes full length MAGE-1, under transcription control of the LTR, and truncated form of human low affinity nerve growth iactor, driven by SV40 promoter. EBV-B cells were transduced with this retroviral vector by cocultivation with irradiated, Ami 2 cells which produced the vector, in the presence of polybrene (0.8mg/ml) for 72 hours. Pure populations of transduced cells were obtained by immunoselection, using anti-LNGFR monoclonal antibodies, and goat- anti-mouse IgG.
  • EBV-B cells transduced with the retro-MAGE-l.NGFR construct used, together with allogeneic EBV-B cells (lxlO 4 LG2-EBV-B cells per well), as feeder cells.
  • Vaccinia virus transfectants as described supra, were tested in a 51 Cr release assay, also as described, supra. Varying effecto ⁇ target ratios were used, ranging from 30:1 to 0.03:1. Cells were labelled with 51 Cr for one hour, and then combined with the T cells, as noted. Chromium release was measured after 4 hours.
  • the blood donor who provided the cells used in the prior experiments had been typed, previously, as HLA-A3, B7, B37, Cw*0602, Cw7.
  • 293-EBNA cells were used, and distributed in flat bottomed microwells, one day before transfection with MAGE-1 cDNA inserted in pcDSR- ⁇ , as described by Takebe, et al, Mol. Cell Biol 8:466-472 (1988), incorporated by reference.
  • the 293-EBNA cells were also cotransfected with cDNA for one of the HLA molecules discussed supra.
  • the cDNA was inserted in pcDNA3.
  • Cw0701 cDNA was inserted in pEBOSpuro, while B3701, and B7 were inserted in pcDNAIAmp.
  • Transfections were carried out in microwells, using 50,000 293-EBNA cells, and 50ng of cDNA for each of the HLA molecules being tested, and MAGE-1, in the presence of 1 ⁇ l lipofectamine.
  • 5000 CTLs were added, in a total volume of lOO ⁇ l of complete IMDM, supplemented with 25U/ml of IL-2.
  • TNF release assay was carried out, in accordance with Traversari. et al., J. Exp. Med. 176:1453-1457 (1992), incorporated by reference, with the exception that 20mM of LiCl was added during incubation of the supernatants with TNF sensitive WEHI 164cl3 cells.
  • the only cells which stimulated the 664/64.7 line were those transfected with both MAGE-A1 and Cw*0602, thus establishing HLA-Cw*0602 as the presenting molecule.
  • This example describes experiments designed to determine the presented peptide.
  • a set of 16 amino acid long, MAGE-1 derived peptides were prepared, using standard solid phase methodologies.
  • the peptides which overlapped by 12 residues and covered the entire MAGE-1 amino acid sequence, were incubated with autologous EBV-B cells that had been labelled with Na( 5I Cr)O 4 .
  • the cells were incubated for 15 minutes in the presence of 1 ⁇ g/ml of peptide, and then tested for lysis with the T cells, at effector :target ratios of 10:1. Chromium release was measured after 4 hours.
  • Dendritic cells expressing MAGE-1 had been used to activate CTL clone 664/64.7. Hence, experiments were designed to verify that tumor cells process the MAGE-1 molecule to the antigen.
  • MZ2-MEL.43 A MAGE-1 expressing tumor cell line, MZ2-MEL.43 was obtained from a patient who tested positive for HLA-Cw6 expression. These cells either were, or were not contacted with gamma interferon (lOOU/ml), 48 hours before lysis studies. EBV-B cells were also used. These cells naturally produce TNF. They were fixed with PFA (1% in PBS) for 10 minutes at room temperature, washed twice with Hank's medium, and either pulsed or not with the shorter peptide.
  • PFA 1% in PBS
  • Stimulator cells (2x10 4 ) were distributed in flat bottom microwells, and cocultured with 5,000 CTLs, in a total volume of 150 ⁇ l of complete IMDM, supplemented with 25U/ml of IL-2.
  • TNF production was measured, following overnight co-culture, by testing for toxicity of supernatant on TNF sensitive, WEHI 164 clone 13 cells.
  • the MAGE-1 expressing tumor line from the HLA-Cw6 positive patient exhibited high production of the TNF by the CTL, either with or without gamma interferon.
  • the EBV-B cells did stimulate TNF production when the peptide was used.
  • the peptide in question i.e., SAYGEPRKL
  • SAYGEPRKL has previously been identified as a CTL epitope for HLA-Cw3 and HLA-Cwl6. See Chaux, et al., supra: van der Bruggen. et al., supra. These data show that the molecule can now be extended to HLA-Cw6.
  • the foregoing disclosure sets forth various features of the invention. These include isolated peptides which are processed to peptides that form immunogenic complexes with HLA-B 18 and/or Cw6 molecules.
  • the peptides of the invention may comprise the first 10 amino acids of SEQ ID NO: 1, i.e.:
  • MEVDPIGLHY concatenated to from 1 to 30 additional amino acids at the N (Met) or C (Tyr) terminus, preferably from 5-10 additional amino acids, such as the peptide of SEQ ID NO: 1.
  • the concatenated amino acids are identical to the amino acid sequence which precedes Met or follows Tyr in the full length amino acid sequence of MAGE-3, but the concatenated amino acids also accommodate variations, such as conservative suDStitutions, deletions, additions and so forth.
  • the peptides of the invention possess the functional properties of being taken up by antigen presenting cells, such as dendritic cells, and being processed to the 10 amino acid sequence described supra.
  • the cells which take up the peptides are cells which present HLA-B 18 molecules on their surface.
  • the 10 amino acid peptide referred to herein is also presented by HLA-B44 cells, so the cells may be those which are positive for either HLA-B 18 or HLA-B44, or both.
  • cytolytic T cells which are specific for complexes of HLA-B 18 molecules and the 10 amino acid sequence referred to supra, which do not recognize other complexes, including complexes of the sequence and different HLA molecules. As was shown, supra, such cytolytic T cells can be prepared using standard methodologies, including those described herein.
  • peptides of the invention comprise amino acids 6-14 of SEQ ID NO: 2, i.e.:
  • SAYGEPRKL concatenated to from 1 to 20 additional amino acids at the N (Ser) or C (Leu) terminus, preferably from 5-10 additional amino acids, such as the peptides of SEQ ID NOS: 2 and 3.
  • the concatenated amino acids are identical to the amino acid sequence which precedes Ser or follows Leu in the full length amino acid sequence of MAGE-1, but the concatenated amino acids also accommodate variations, such as conservative substitutions, deletions, additions and so forth.
  • the peptides of the invention possess the functional properties of being taken up by antigen presenting cells, such as dendritic cells, and being processed to the 10 amino acid sequence described supra.
  • the cells which take up the peptides are cells which present HLA-Cw6 molecules on their surface, which makes the peptide more useful than previously, as it can be used in connection with HLA-Cw6 molecules, as well as those which present HLA-Cw3, or HLA-Cwl6.
  • the 9 amino acid peptide referred to herein is also presented by HLA-Cw3 and Cwl6 positive cells, so the cells may also be those which are positive for both HLA-Cw6 and at least one of HLA-Cw3 and HLA- Cwl6.
  • cytolytic T cell lines of the invention various methods can be used to identify and to secure these. Such methodologies include, i.e., FACS or other analytical methods, preferably in combination with molecules, such as tetrameric compounds of avidin or streptavidin, biotin, and HLA/peptide complexes, to identify relevant CTLs from samples.
  • the ability of the peptides to form recognizable complexes makes them useful as therapeutic agents in conditions such as cancer, including melanoma, lung, breast, head and neck, and other cancer types, such as those described in, e.g., Principals and Practic of The Biologic Therapy of Cancer (Lippincott Williams and Wilkens, 3 rd ed., 2000), p. 499, incorporated by reference, where the peptide forms a complex with the HLA molecule, leading to recognition by a CTL, and lysis thereby.
  • cancer including melanoma, lung, breast, head and neck
  • other cancer types such as those described in, e.g., Principals and Practic of The Biologic Therapy of Cancer (Lippincott Williams and Wilkens, 3 rd ed., 2000), p. 499, incorporated by reference, where the peptide forms a complex with the HLA molecule, leading to recognition by a CTL, and lysis thereby.
  • Such subjects may be, e.g., cancer patients, such as melanoma patients.
  • Such patients may receive the peptide of the invention, or "cocktails" which comprise more than one peptide, as long as the peptide cocktail includes the peptide of the invention.
  • the peptide component of such cocktails may consist of the peptides described herein, or may combine some peptides disclosed herein with other peptides known in the art, such as the following, which bind to Class I or Class II MHC.
  • peptides such as those set forth at SEQ ID NOS: 3-36 would be expected to bind to other HLA-Class I or II alleles, such as HLA-A1, A3, B7, B8, B15, B27, B44, B51 in addition to HLA-A2, and subtypes thereof.
  • one or more peptides which bind to HLA-A2, HLA-B7, and so forth can be admixed, preferably in the presence of an adjuvant like GM-CSF, alum, or another adjuvants well known to the art, such as CpG.
  • an adjuvant like GM-CSF, alum, or another adjuvants well known to the art, such as CpG.
  • an adjuvant like GM-CSF, alum, or another adjuvants well known to the art, such as CpG.
  • an adjuvant like GM-CSF, alum, or another adjuvants well known to the art, such as CpG.
  • an adjuvant like GM-CSF, alum, or another adjuvants well known to the art, such as CpG.
  • therapeutic agents are peptide pulsed, autologous dendritic cells. See, e.g., Jonuleit. et al., Int.
  • cytolytic T cells specific for the amino acids 1-10 of SEQ ID NO: 1 and HLA-B18 or HLA-Cw6 and amino acids 6-14 of SEQ ID NO: 2 complexes, such as autologous CTLs, which can be prepared as described in the preceding examples.
  • CTLs which are specific for complexes of the first 10 amino acids of SEQ ID NO: 1 and HLA-B18, or amino acids 6-14 of SEQ ID NO: 2, HLA-Cw6 and no other complexes, are a further feature of the invention.
  • nucleic acid molecules which consist of nucleotide sequences that encode the peptides of the invention.
  • Such nucleic acid molecules may be used to encode the peptides of the invention, and may be combined into expression vectors, operably lined to a promoter. More than one sequence can be combined in such expression vectors, as can nucleic acid molecules which encode HLA- B18 or HLA-Cw6 molecules.
  • the constructs can be used to transfect cells, so as to generate the CTLs, or for administration to subjects in need of a cytolytic T cell response or augmenting of a pre-existing T cell response.
  • Such administration could be one of, e.g., administering vector constructs as described, heterologous expression vectors, peptides or recombinant proteins, such as the full length proteins, preferably in recombinant form, from which one or more of the peptides are derived as discussed supra.
  • the invention also relates to the use of the peptides, CTLs, and other, immunologically active components, such as antibodies, to diagnose pathological conditions such as cancer, melanoma in particular.
  • pathological conditions such as cancer, melanoma in particular.
  • MAGE-1 are expressed in cancer cells and the presence of complexes of the first 10 aiiSimo acids of SEQ ID NO: 1 and HLA-B18 and/or HLA-Cw6 and amino acids 6-14 of
  • SE(J J NO: 2 is indicative of a pathological condition.
  • the im ⁇ iunologically active component and the complex by way of, e.g., antibody binding, TH ⁇ F release, cell lysis, etc., one can diagnose the pathology, or even determine the status of the pathology via comparing a value to a pre-existing value for the same parameter.
  • the invention also embraces functional variants of the MAGE-3 and MAGE-1 HLA class I binding peptides.
  • a "functional variant” or “variant” of a MAGE-3 HLA class I binding peptide is a peptide which contains one or more modifications to the primary amino acid sequence of MAGE-3 or MAGE-1 HLA class I binding peptide and retains the HLA class I and T cell receptor binding properties disclosed herein.
  • Modifications which create a MAGE-3/MAGE-1 HLA class I binding peptide functional variant can be made for example 1) to enhance a property of a MAGES/MAGE- 1 HLA class I binding peptide, such as peptide stability in an expression system or the stability of protein-protein binding such as HLA-peptide binding; 2) to provide a novel activity or property to a MAGE-3/MAGE-1 class I binding peptide, such as addition of an antigenic epitope or addition of a detectable moiety; or 3) to provide a different amino acid sequence that produces the same or similar T cell stimulatory properties.
  • a MAGES/MAGE- 1 HLA class I binding peptide such as peptide stability in an expression system or the stability of protein-protein binding such as HLA-peptide binding
  • 2) to provide a novel activity or property to a MAGE-3/MAGE-1 class I binding peptide such as addition of an antigenic epitope or addition of a detectable moiety
  • Modifications ' to a MAGE-3 HLA class I binding peptide can be made a nucleic acid which encodes the peptide, and can include deletions, point mutations, truncations, amino acid substitutions and additions of amino acids. Alternatively, modifications can be made directly to the polypeptide, such as by cleavage, addition of a linker molecule, addition of a detectable moiety, such as biotin, addition of a fatty acid, substitution of one amino acid for another and the like. Modifications also embrace fusion proteins comprising all of part of the MAGE-3/MAGE-1 HLA class I binding peptide amino acid sequence.
  • the amino acid sequence of MAGE-3/MAGE-1 HLA class I binding peptides may be of natural or non-natural origin, that is, they may comprise a natural MAGES/MAGE- 1 HLA class I binding peptide molecule or may comprise a modified sequence as long as the amino acid sequence retains the ability to stimulate T cells when presented and retains the property of binding to an HLA class I molecule such as an HLA-B 18, B44, Cw6, Cw3 or Cwl6 molecule.
  • MAGE-3 HLA class I binding peptides in this context may be fusion proteins of a MAGE-3/MAGE-1 HLA class I binding peptide and unrelated amino acid sequences, a synthetic peptide of amino acid sequences shown in SEQ ID NO: 1, 2 or 3, the sequence MEVDPIGHLY or SAYGEPRKL, labeled peptides, peptides isolated from patients with a MAGE-3 or MAGE-1 expressing cancer, peptides isolated from cultured cells which express MAGE-3 or MAGE-1, peptides coupled to nonpeptide molecules (for example in certain drug delivery systems) and other molecules which include the amino acid sequence of MEVDPIGHLY, or SAYGEPRKL.
  • MAGE-3 or MAGE-1 HLA class I binding peptides are non- hydrolyzable.
  • MAGE-3 or MAGE-1 HLA class I binding peptides are selected from a library of non-hydrolyzable peptides, such as peptides containing one or more D-amino acids or peptides containing one or more non- hydrolyzable peptide bonds linking amino acids.
  • non-hydrolyzable peptide bonds are known in the art, along with procedures for synthesis of peptides containing such bonds.
  • Non-hydrolyzable bonds include - psi[Ch.sub.2 NH]-reduced amide peptide bonds, -psi[COCH.sub.2]- ketomethylene peptide bonds, -psi[CH(CN)NH]- (cyanomethlylene) amino peptide bonds, -psi[CH.sub.2CH(OH)]-hydroxyethylene peptide bonds, -psi[CH.sub.2 O]-peptide bonds, and -psi[CH.sub.2 S]-thiomethylene peptide bonds.
  • a variant involves a change to an amino acid of SEQ ID NO: 1, 2 or 3, the sequence MEVDPIGHLY or the sequence SAYGEPRKL
  • functional variants of the MAGE-3 or MAGE-1 HLA class I binding peptide having conservative amino acid substitutions typically will be preferred, i.e., substitutions which retain a property of the original amino acid such as charge, hydrophobicity, conformation, etc.
  • conservative substitutions of amino acids include substitutions made amongst amino acids within the following groups: (a) M, I, L, V; (b) F, Y, W: (c) K, R, H; (d) A, G; (e) S, T: (f) Q, N; and (g) E, D.
  • the methods include selecting a MAGE- 3 or MAGE-1 HLA class I binding peptide, an HLA class I binding molecule which binds the MAGE-3 or MAGE-1 HLA class I binding peptide, and a T cell which is stimulated by the MAGE-3 or MAGE-1 HLA class I binding peptide presented by the HLA class I binding molecule.
  • the MAGE-3 or MAGE-1 HLA class I binding peptide comprises the amino acid sequence of amino acids 6-14 of SEQ ID NO: 2 or amino acids 1-10 of SEQ ID NO: 1.
  • the peptide consists of the amino acid sequence of MEVDPIGHLY or SAYGEPRKL.
  • a first amino acid residue of tne MAGE-3 HLA class I binding peptide is mutated to prepare a variant peptide. Any method for preparing variant peptides can be employed, such as synthesis of the variant peptide, recombinantly producing the variant peptide using a mutated nucleic acid molecule, and the like.
  • the binding of the variant peptide to HLA class I binding molecule and stimulation of the T cell are then determined according to standard procedures wherein binding of the variant peptide to the HLA class I binding molecule and stimulation of the T cell by the variant peptide presented by the HLA class I binding molecule indicates that the variant peptide is a functional variant.
  • the variant peptide can be contacted with an antigen presenting cell which contains the HLA class I molecule which binds the MAGE-3 or MAGE-1 peptide to form a complex of the variant peptide and antigen presenting cell.
  • This complex can then be contacted with a T cell which recognizes the epitope formed by the MAGE-3 HLA class I binding peptide and the HLA class I binding molecule.
  • T cells can be obtained from a patient having a condition characterized by expression of MAGE-3 or MAGE-1. Recognition of variant peptides by the T cells can be determined by measuring an indicator of T cell stimulation.
  • Binding of the variant peptide to the HLA class I binding molecule and stimulation of the T cell by the epitope presented by the complex of variant peptide and HLA class I binding molecule indicates that the variant peptide is a functional variant.
  • the methods also can include the step of comparing the stimulation of the T cell by the epitope formed by the MAGE-3 or MAGE-1 HLA class I binding peptide and the HLA class I molecule, stimulation of the T cell as a determination of the effectiveness of the stimulation of the T cell by the epitope. By comparing the epitope involving the epitope formed by the functional variant with the MAGE-3 or MAGE-1 HLA class I binding peptide, peptides with increased T cell stimulatory properties can be prepared.
  • Variants of the MAGE-3 or MAGE-1 HLA class I binding peptides prepared by any of the foregoing methods can be sequenced, if necessary, to determine the amino acid sequence and thus deduce the nucleotide sequence which encodes such variants.

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Microbiology (AREA)
  • Molecular Biology (AREA)
  • Oncology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Cell Biology (AREA)
  • Organic Chemistry (AREA)
  • Biomedical Technology (AREA)
  • Mycology (AREA)
  • Hematology (AREA)
  • Veterinary Medicine (AREA)
  • Analytical Chemistry (AREA)
  • Biochemistry (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pathology (AREA)
  • Epidemiology (AREA)
  • Urology & Nephrology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Zoology (AREA)
  • Genetics & Genomics (AREA)
  • Biotechnology (AREA)
  • Physics & Mathematics (AREA)
  • General Physics & Mathematics (AREA)
  • Biophysics (AREA)
  • Food Science & Technology (AREA)
  • Wood Science & Technology (AREA)
  • Hospice & Palliative Care (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Engineering & Computer Science (AREA)
  • Toxicology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)

Abstract

La présente invention concerne des peptides, identifiés auparavant comme des partenaires de liaison des molécules HLA-B44, HLA-Cw3 et HLS-Cw16. On a découvert que ces peptides se lient aux molécules HLA-B18 et HLA-Cw6, formant des épitopes de lymphocyte T. La présente invention concerne les ramifications thérapeutiques et diagnostiques de cette découverte ainsi que divers produits obtenus au cours de la mise en valeur de cette invention.
PCT/US2003/017641 2002-06-05 2003-06-04 Peptides presentes par des molecules hla-b18 et hla-cw16 et utilisations de ces peptides WO2003104259A2 (fr)

Priority Applications (1)

Application Number Priority Date Filing Date Title
AU2003249693A AU2003249693A1 (en) 2002-06-05 2003-06-04 PEPTIDES PRESENTED BY HLA-B18 AND Cw16 MOLECULES, AND USES THEREOF

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US10/164,121 2002-06-05
US10/164,121 US20030228308A1 (en) 2002-06-05 2002-06-05 Isolated peptides which bind to HLA-Cw6 molecules and uses thereof
US10/164,078 US7041502B2 (en) 2002-06-05 2002-06-05 Isolated peptides which bind to HLA-B18 molecules and uses thereof
US10/164,078 2002-06-05

Publications (2)

Publication Number Publication Date
WO2003104259A2 true WO2003104259A2 (fr) 2003-12-18
WO2003104259A3 WO2003104259A3 (fr) 2004-07-08

Family

ID=29738933

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2003/017641 WO2003104259A2 (fr) 2002-06-05 2003-06-04 Peptides presentes par des molecules hla-b18 et hla-cw16 et utilisations de ces peptides

Country Status (2)

Country Link
AU (1) AU2003249693A1 (fr)
WO (1) WO2003104259A2 (fr)

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5750395A (en) * 1993-08-06 1998-05-12 Cytel Corporation DNA encoding MAGE-1 C-terminal cytotoxic t lymphocyte immunogenic peptides
US6303756B1 (en) * 1998-07-27 2001-10-16 Ludwig Institute For Cancer Research Tumor associated nucleic acids and uses therefor
US20030228325A1 (en) * 2002-06-05 2003-12-11 Janine Bilsborough Isolated peptides which bind to HLA-B18 molecules and uses thereof

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5750395A (en) * 1993-08-06 1998-05-12 Cytel Corporation DNA encoding MAGE-1 C-terminal cytotoxic t lymphocyte immunogenic peptides
US6303756B1 (en) * 1998-07-27 2001-10-16 Ludwig Institute For Cancer Research Tumor associated nucleic acids and uses therefor
US20030228325A1 (en) * 2002-06-05 2003-12-11 Janine Bilsborough Isolated peptides which bind to HLA-B18 molecules and uses thereof

Also Published As

Publication number Publication date
AU2003249693A8 (en) 2003-12-22
AU2003249693A1 (en) 2003-12-22
WO2003104259A3 (fr) 2004-07-08

Similar Documents

Publication Publication Date Title
US7371845B2 (en) MAGE-A3 peptides presented by HLA class II molecules
EP0711173B1 (fr) Peptides isoles formant des complexes avec la molecule mhc du clone hla-c 10 et utilisation de ceux-ci
EP1012283B1 (fr) Peptides de mage-3 presentes par des molecules de classe ii de hla
JP3433322B2 (ja) 腫瘍拒絶抗原先駆体をコード化する核酸分子
JP4652390B2 (ja) Ｈｌａクラスｉｉ分子により提示されるｍａｇｅ−ａ１ペプチド
EP1119623B1 (fr) Peptides du gene mage-a3 presentes par les molecules de hla classe ii
US9404925B2 (en) Cancer antigen and use thereof
JP3096739B2 (ja) Ｈｌａ分子によって提示される単離ノナペプチドとその使用
DK2186889T3 (en) CDCA1 PEPTID AND PHARMACEUTICAL COMPOSITION, INCLUDING THIS
US6770456B1 (en) Endogenous retrovirus tumor associated nucleic acids and antigens
US7311914B2 (en) MAGE-A4 antigenic peptides and uses thereof
KR20020047249A (ko) Ｍａｇｅ-ａ12 항원성 펩티드 및 그의 용도
KR19990087064A (ko) Hla-b４４ 분자에 의해 인식되는 종양 거부 항원 및그 용도
US7041502B2 (en) Isolated peptides which bind to HLA-B18 molecules and uses thereof
US20050249743A1 (en) Isolated peptides which bind to HLA-A24 molecules and uses thereof
WO2003104259A2 (fr) Peptides presentes par des molecules hla-b18 et hla-cw16 et utilisations de ces peptides
US7488793B2 (en) Isolated peptide which binds to HLA-Cw*07 and uses thereof
US6897288B1 (en) Mage-A12 antigenic peptides and uses thereof
JP3355360B2 (ja) 単離ペプチド
EP1165776A1 (fr) PEPTIDES ANTIGENIQUES EphA3 DE RECEPTEUR DE TYROSINE KINASE
JPWO2003008450A1 (ja) 腫瘍抗原
US20030228308A1 (en) Isolated peptides which bind to HLA-Cw6 molecules and uses thereof
WO2000013699A1 (fr) Peptide antigenique code par un autre cadre de lecture ouvert de facteur stimulant la proliferation des macrophages
AU2002339748A1 (en) MAGE-A3 peptides presented by HLA class II molecules

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AU CA JP

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IT LU MC NL PT RO SE SI SK TR

121 Ep: the epo has been informed by wipo that ep was designated in this application
DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
122 Ep: pct application non-entry in european phase
NENP Non-entry into the national phase

Ref country code: JP

WWW Wipo information: withdrawn in national office

Country of ref document: JP